Dr. Gordon Presents BOT/BAL Data: 39% Alive at 2 Years in Refractory Solid Tumors | ESMO 2025

At the ESMO Congress 2025 in Berlin, Dr. Michael Gordon, Chief Medical Officer at the HonorHealth Research Institute, presented updated results from Agenus’ Phase 1b C-800-01 study evaluating botensilimab (BOT) and balstilimab (BAL) in more than 400 patients with advanced refractory solid tumors. Hear him deliver his presentation along with slides from ESMO 2025 Abstract #1517MO).